Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Jose Mayordomo"'
Autor:
Anthony D. Elias, Nicole S. Spoelstra, Alyse W. Staley, Sharon Sams, Lyndsey S. Crump, Gregory A. Vidal, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D’Alessandro, Kathryn L. Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Dexiang Gao, Jennifer K. Richer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulv
Externí odkaz:
https://doaj.org/article/ad0c82b5d82a4e81a6170a0a923d1435
Autor:
Funda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, Do-Youn Oh, Diana L Hanna, Yoon-Koo Kang, Elena Elimova, Jorge Chaves, Rachel Goodwin, Jeeyun Lee, Lisle Nabell, Sun Young Rha, Jose Mayordomo, Anthony El-Khoueiry, Shubham Pant, Kanwal Raghav, Jin Won Kim, Amita Patnaik, Todd Gray, Rupert Davies, Mark A Ozog, Joseph Woolery, Keun-Wook Lee
Publikováno v:
The Lancet Oncology. 23:1558-1570
HER2-targeted therapies have substantially improved outcomes for patients with HER2-positive breast and gastric or gastro-oesophageal junction cancers. Several other cancers exhibit HER2 expression or amplification, suggesting that HER2-targeted agen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecbe474d30e9ab9eec0ed1eddc6923d9
https://doi.org/10.1016/s1470-2045(22)00621-0
https://doi.org/10.1016/s1470-2045(22)00621-0
Autor:
Elena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew Brenner, Alison Stopeck, Jose Mayordomo, Jennifer Diamond, Peter Kabos, Virginia F. Borges
Publikováno v:
Cancer Research. 82:P1-18
Background: The phase IB/II clinical trial of tucatinib, palbociclib and letrozole (NCT03054363) showed activity in heavily pretreated patients (pts) with HR+/HER2+ metastatic breast cancer (Shagisultanova et. al, Cancer Res 2021:81(4), PS10-03). Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21d82fe75875a4d0dbb7ae31807ec144
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-26
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-26
Autor:
Jennifer Richer, Nicole Spoelstra, Alyse Winchester, Julia Wulfkuhlue, Rosa Gallagher, Sharon Sams, Gregory Vidal, Peter Kabos, Jennifer Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadded, Gloria Crawford, Virginia Borges, Dexiang Gao, Emanuel Petricoin, Anthony Elias
Publikováno v:
Cancer Research. 82:P1-17
Background: The clinical implications of the androgen receptor (AR), particularly in the context of aromatase inhibitor (AI) refractory metastatic breast cancer (MBC), are unclear. While AR is associated with more indolent primary tumors, in the abse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abe63f468ac7349b194565e8752303fd
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-01
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-01
Autor:
Philippe L Bedard, Seock-Ah Im, Elena Elimova, Sun Young Rha, Rachel Goodwin, Cristiano Ferrario, Keun-Wook Lee, Diana Hanna, Funda Meric-Bernstam, Jose Mayordomo, Murali Beeram, Erika Hamilton, Jorge Chaves, Melody Cobleigh, Tony Mwatha, Joseph Woolery, Do-Youn Oh
Publikováno v:
Cancer Research. 82:P2-13
Background: Despite the availability of multiple HER2-targeted therapies, most patients (pts) with advanced HER2-positive BC experience disease progression, and an unmet medical need remains. Zanidatamab (zani) binds to HER2 across a range of express
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4800e5f4e861859baa74d541b38c2fa8
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-07
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-07
Autor:
Li-Shiun Chen, Timothy Baker, Rayjean J. Hung, Amy Horton, Robert Culverhouse, Sarah Hartz, Nancy Saccone, Iona Cheng, Bo Deng, Younghun Han, Helen M. Hansen, Janet Horsman, Claire Kim, Albert Rosenberger, Katja K. Aben, Angeline S. Andrew, Shen-Chih Chang, Kai-Uwe Saum, Hendrik Dienemann, Dorothy K. Hatsukami, Eric O. Johnson, Mala Pande, Margaret R. Wrensch, John McLaughlin, Vidar Skaug, Erik H. van der Heijden, Jason Wampfler, Angela Wenzlaff, Penella Woll, Shanbeh Zienolddiny, Heike Bickeböller, Hermann Brenner, Eric J. Duell, Aage Haugen, Irene Brüske, Lambertus A. Kiemeney, Philip Lazarus, Loic Le Marchand, Geoffrey Liu, Jose Mayordomo, Angela Risch, Ann G. Schwartz, M. Dawn Teare, Xifeng Wu, John K. Wiencke, Ping Yang, Zuo-Feng Zhang, Margaret R. Spitz, Christopher I. Amos, Laura J. Bierut
Publikováno v:
EBioMedicine, Vol 11, Iss C, Pp 219-226 (2016)
Background: Recent meta-analyses show that individuals with high risk variants in CHRNA5 on chromosome 15q25 are likely to develop lung cancer earlier than those with low-risk genotypes. The same high-risk genetic variants also predict nicotine depen
Externí odkaz:
https://doaj.org/article/1e6abb3bfd8c4e62bba549139ca29454
Autor:
Colleen Murphy, Jennifer R. Diamond, Nicole Kounalakis, Rachel Rabinovitch, Virginia F. Borges, Anthony D. Elias, Peter Kabos, Christine M. Fisher, Jose Mayordomo, Christina Finlayson
Publikováno v:
Breast Cancer Management. 3:205-212
SUMMARY Given the generally excellent outcomes for modern breast cancer treatment, the recognition that overtreatment is commonplace is the driving force to reduce the treatment impact of surgery, radiation therapy and chemotherapy. Many recent trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cad52575cd93620d047a331e75f9a605
https://doi.org/10.2217/bmt.13.83
https://doi.org/10.2217/bmt.13.83
Publikováno v:
Cancer. 72:1637-1641
Background. Twenty-six patients with desmoid tumors of the extremities (n = 20) or trunk (n = 6) have been treated since 1977. Nine of these were referred with primary tumors and 17 with recurrent tumors. Methods. The tumor was removed in all patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbed45621666fdffcaf827f198a6d7c9
https://doi.org/10.1002/1097-0142(19930901)72:5<1637::aid-cncr2820720524>3.0.co
https://doi.org/10.1002/1097-0142(19930901)72:5<1637::aid-cncr2820720524>3.0.co
Autor:
Frank Buntinx, Paolo Vineis, Steinunn Thorlacius, Anne Kiltie, Augustine Kong, Unnur Thorsteinsdottir, Rajiv Kumar, Stefano Porru, Giuseppe Matullo, Frank Geller, Katja K.H. Aben, Thorunn Rafnar, Tony Fletcher, P. Rudnai, Timothy Bishop, Patrick Sulem, Eugene Gurzau, Jeffrey Gulcher, Jose Mayordomo, Maurice Zeegers, Gunnar Steineck, Kvetoslava Koppova, L.A.L.M. Kiemeney, K. Stefansson
Publikováno v:
Cancer Prevention Research. 1:PR-7
PR-7 We conducted a genome-wide SNP association study on 1,803 urinary bladder cancer (UBC) cases and 34,336 controls from Iceland and the Netherlands using Illumina HumanHap300 and HumanCNV370-duo Beadchips. The 10 most significant SNPs were genotyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74a7b66b706b259dd57661e6565d3e51
https://doi.org/10.1158/1940-6207.prev-08-pr-7
https://doi.org/10.1158/1940-6207.prev-08-pr-7
Autor:
Elias, Anthony D., Spoelstra, Nicole S., Staley, Alyse W., Sams, Sharon, Crump, Lyndsey S., Vidal, Gregory A., Borges, Virginia F., Kabos, Peter, Diamond, Jennifer R., Shagisultanova, Elena, Afghahi, Anosheh, Mayordomo, Jose, McSpadden, Tessa, Crawford, Gloria, D'Alessandro, Angelo, Zolman, Kathryn L., van Bokhoven, Adrie, Zhuang, Yonghua, Gallagher, Rosa I., Wulfkuhle, Julia D.
Publikováno v:
NPJ Breast Cancer; 5/20/2023, Vol. 9 Issue 1, p1-10, 10p